Skip to main content
. 2021 Mar 25;188(1):117–131. doi: 10.1007/s10549-021-06184-w

Fig. 1.

Fig. 1

Study flow and patient disposition. aGroup A included patients aged < 65 years and with HRD score ≥ 42, and all patients with gBRCAm. bGroup B included patients aged < 65 years and with HRD score < 42, and all patients aged ≥ 65 years except those with gBRCAm. gBRCAm, germline BRCA mutation; CPR, centralized pathologic review; ER, estrogen receptor; FAS, full analysis set; HER2, human epidermal growth factor receptor 2; HRD, homologous recombination deficiency; PgR, progesterone receptor; SAF, safety analysis set